This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Experienced Surgeon Vs. FDA-Approved Robot

NEW YORK, April 11, 2013 /PRNewswire/ -- With more than 4,500 robotic prostate surgeries under his belt, David Samadi, MD may be the last person you'd expect to welcome an FDA investigation of robotic surgery. But late Tuesday he appeared on Fox 5 News saying, "Let the FDA do their investigation and clear the air. This is about our prostate cancer patients."

(Photo: http://photos.prnewswire.com/prnh/20130411/NY93298 )

Dr. David Samadi is Vice Chairman of the Department of Urology and Chief of Robotics and Minimally Invasive Surgery at Mount Sinai Medical Center. He was among the first in the world to perform robotic prostate surgery and today he uses the da Vinici robot in his highly successful SMART (Samadi Modified Advanced Robotic Technique) version of the procedure.

Dr. Samadi offers these key questions for patients to ask their prospective surgeon:

  1. How many successful robotic surgeries have you performed?
  2. Will I be your only patient/operating room during my procedure?
  3. What are the typical complications following your robotic surgeries?

Over the past few years, hospitals have invested big money in procuring and promoting surgical robots, but enthusiasm for the technology may be waning amid reports of robotic surgery mistakes and deaths. In 2012, the nationwide count for robotic surgeries hit almost 400,000. Some experts say more robotic procedures are bound to result in increased data on negative surgical outcomes. But is it really a matter of odds or just an excuse for surgeon inexperience and limited training requirements?

Dr. Samadi stands by the robot, instead directing patient focus to the surgeon and the hospital. Stressing the surgeon-robot duo he says, "The technology is safe; you have to know how to use it."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs